Skip to content

hEDS: Comorbidities, Disease Trajectories, and Pathomechanisms — Literature Review

Date: 2026-07-28. Scope: hypermobile Ehlers-Danlos syndrome (hEDS) and the closely adjacent hypermobility spectrum disorders (HSD). Sources retrieved from PubMed; every claim below is anchored to a PMID whose abstract was read directly.

Executive summary

  1. The comorbidity picture is well described but weakly mechanistically explained. Every major review converges on the same multisystem cluster — chronic pain, fatigue, dysautonomia/POTS, disorders of gut–brain interaction (DGBI), mast cell activation, anxiety/neurodevelopmental conditions — but the 2025 AGA expert review states plainly that "experimental evidence of the biological mechanisms that explain relationships is limited and evolving" (PMID:40387691).
  2. The "trifecta" (hEDS + POTS + MCAS) is contested, not settled. It is simultaneously the organising frame of the clinical literature and the target of a substantive skeptical review arguing the association is an artifact of overlapping subjective symptom pools (PMID:31267471). Any dismech curation must represent both positions.
  3. Objective physiological findings are stronger than the nosology. The largest instrumented hEDS series (n=270) found reduced orthostatic cerebral blood flow velocity in 79%, POTS in 33%, and small fiber neuropathy in 64–82% (PMID:40843452) — these are measurements, not symptom checklists, and they are the most defensible mechanistic anchors currently available.
  4. Trajectory evidence is thin. The only explicit natural-history staging model (hypermobility → pain → stiffness phases) rests on a 21-patient pilot from 2010 (PMID:20140961). There is no large longitudinal cohort establishing directionality between hEDS and its comorbidities. Sequence claims should be curated as hypotheses.
  5. The first common-variant genetics arrived in 2025 and is still a preprint. A GWAS meta-analysis (1,815 cases / 5,008 controls) reports two genome-wide significant loci and — importantly for comorbidity modeling — LD-score genetic correlations with ME/CFS, fibromyalgia, depression, anxiety, ASD, migraine, and GI disease (PMID:41001447). Preprint status must be flagged if used.

1. Comorbidities

1.1 The multisystem cluster

The Mayo/MUSC registry study is the largest systematic comorbidity dataset: 2,149 clinically diagnosed hEDS patients, self-reported survey, K-means clustering. It identified three distinct phenotypic clusters and — a notable negative result — concluded that Beighton scores are unreliable for multimorbidity phenotyping (PMID:38779137). This matters for dismech: joint-laxity severity does not index multisystem burden, so a comorbidity model keyed on hypermobility score would be mis-specified.

Caveats: cross-sectional, self-reported, registry-recruited (ascertainment bias toward severely affected and highly engaged patients), and clinically — not genetically — diagnosed.

1.2 Gastrointestinal (best-quantified comorbidity)

A systematic review reports GI symptom prevalences in HSD/hEDS versus non-HSD/hEDS comparators (PMID:35750466):

Symptom HSD/hEDS Comparator p
Abdominal pain 69% 27% <0.0001
Constipation 73% 16% <0.001
Diarrhea 47% 9% <0.001
Postprandial fullness 34% 16% 0.01

The dominant GI phenotype is disorders of gut–brain interaction, particularly functional dyspepsia — not structural bowel disease. Proposed contributors: connective tissue laxity and its functional consequences, autonomic dysfunction, medication effects, and comorbid mental health disorders (PMID:35750466).

The 2025 AGA Clinical Practice Update adds two specific, testable GI observations (PMID:40387691): - Pelvic floor dysfunction, especially rectal hyposensitivity, is highly prevalent — it recommends anorectal manometry/balloon expulsion/defecography for lower GI symptoms. - Abnormal gastric emptying may be more common than in the general population, in hEDS/HSD patients with comorbid POTS specifically.

It also advises earlier celiac testing in hEDS/HSD across GI presentations, not only diarrhea — a concrete co-occurrence signal (celiac disease is already in kb/disorders/).

1.3 Dysautonomia / POTS

Reviews frame neurocardiovascular dysautonomia — chiefly POTS — as a core hEDS comorbidity, and note that POTS onset is often linked to a discrete precipitating event: infection, trauma, surgery, or stress (PMID:34766441). That is the closest thing in this literature to a mechanistic trajectory trigger.

The instrumented Brigham series (270 hEDS patients vs 29 controls) is the strongest objective dataset (PMID:40843452):

Finding Prevalence in hEDS
Reduced orthostatic cerebral blood flow velocity 79%
Widespread but mild autonomic failure on testing 90%
POTS on head-up tilt 33%
Hypocapnic cerebral hypoperfusion 22%
Orthostatic cerebral hypoperfusion syndrome 18%
Neurogenic orthostatic hypotension 9%
Small fiber neuropathy (structural criteria) 64%
Small fiber neuropathy (structural + functional) 82%

Two things stand out. First, cerebral hypoperfusion is more prevalent than POTS itself — orthostatic symptoms in hEDS are not reducible to heart-rate criteria. Second, small fiber neuropathy at 64–82% is a candidate unifying substrate linking autonomic dysfunction, chronic pain, and GI dysmotility. The existing dismech hEDS entry carries Peripheral neuropathy (HP:0009830) but not small fiber neuropathy specifically.

Caveat: tertiary autonomic-referral population; the control arm (n=29) is small.

1.4 Mast cell activation

This is the weakest link in the triad, and the literature is openly split.

For: A retrospective chart review (195 records) found MCAS in 31% of the POTS+EDS group versus 2% of the non-POTS/EDS group, OR 32.46 (PMID:33980338).

Against: A systematic review of the hEDS–POTS–MCAS literature found that of 88+136 search combinations, only four (narrow) and nine (broad) papers were original research, and no paper resulted from combining search terms for all three conditions. Its conclusion: "current evidence is lacking on the existence of MCAS or hEDS as separate or significant clinical entities," and the apparent association "stems from an overlapping pool of vague, subjective symptoms" (PMID:31267471).

Practice position: The AGA update takes the middle road — clinicians should be aware of the observed associations, but universal POTS/MCAS testing in all hEDS/HSD patients is not supported by current evidence (PMID:40387691). It sets a concrete diagnostic threshold: tryptase at baseline and 1–4 h post-flare, with an increase of 20% above baseline plus 2 ng/mL required to demonstrate mast cell activation.

Mechanistic hypothesis: A mechanobiology review proposes that reduced tissue stiffness in EDS is itself the link to mast cell degranulation — i.e. the comorbidity is a downstream consequence of the matrix defect rather than an independent disease (PMID:35547807). This is a hypothesis, not a demonstrated pathway.

1.5 Chronic pain

Roughly 90% of EDS patients report some form of chronic pain, often as one of the first symptoms, and it is multifactorial: joint subluxations/dislocations, prior surgery, muscle weakness, proprioceptive disorders, vertebral instability, plus generalized body pain, headaches, GI pain, TMJ pain, dysmenorrhea, and vulvodynia (PMID:28186390).

Quantitative sensory testing supports central pain facilitation as a mechanism: 20 women with hEDS versus 20 matched controls showed reduced pressure pain thresholds and significantly increased temporal summation of pain; exercise-induced hypoalgesia was reduced at the quadriceps; conditioned pain modulation results were inconclusive (PMID:35442549). A parallel adolescent feasibility study exists but is methodology-focused and underpowered for prevalence claims (PMID:37316864).

1.6 Fatigue / ME-CFS

Chronic fatigue is a major driver of impaired quality of life, and there is explicit symptom overlap with chronic fatigue syndrome — the review argues that "a proportion of those with CFS likely have EDS that has not been identified" (PMID:28186393). Named contributors: sleep disorders, chronic pain, deconditioning, cardiovascular autonomic dysfunction, bowel and bladder dysfunction, psychological factors, nutritional deficiencies. This is a diagnostic-overlap claim as much as a comorbidity claim, which is exactly the confound that makes hEDS comorbidity curation hard.

1.7 Psychiatric and neurodevelopmental

The strongest and most replicated psychiatric association is anxiety; there is growing but more limited evidence for depression, eating disorders, neurodevelopmental disorders, and alcohol/tobacco misuse (PMID:28186381). The proposed mechanisms are notably not purely psychological: genetic risk, autonomic dysfunction, increased exteroceptive and interoceptive sensitivity, decreased proprioception, and neuroimaging evidence of increased responsiveness in emotion-processing brain regions. The authors name this the "neuroconnective phenotype."

For autism, a systematic review with prevalence meta-analysis (20 studies; 12 of 15 association studies significant) reports (PMID:40145613): - Joint hypermobility in autistic individuals: 22.3% overall, 31% when clinically (not self-) assessed - HSD/EDS in autistic samples: 27.9% overall, 39% when clinically assessed

1.8 Migraine

Migraine is described as one of the most common comorbidities of POTS, HSD, and MCAS, and conversely these are prevalent in migraine patients with multisystem symptoms (PMID:37847487). This is a review-level claim about a shared cluster rather than an independent effect estimate.

1.9 Respiratory (under-recognized)

One case-control study estimated twofold to threefold greater respiratory disease burden in EDS versus controls (PMID:34811894). Mechanistically distinct arms: structural (pectus deformity, scoliosis, recurrent rib subluxation, tracheobronchomalacia), functional aerodigestive (inducible laryngeal obstruction misdiagnosed as asthma, with GE dysmotility/reflux contributing), inflammatory (costochondritis, bronchiectasis, localized mast cell activation), and neurological (craniocervical instability dysregulating respiratory control pathways).

2. Disease trajectories

2.1 The three-phase model — and its evidentiary weight

The only explicit natural-history staging in this literature comes from a 21-patient pilot study proposing three phases distinguished by dominant manifestations (PMID:20140961):

  1. Hypermobility phase
  2. Pain phase
  3. Stiffness phase

The same study identified Arnold-Chiari type I malformation, dolichocolon, and dysphonia as additional, apparently uncommon findings. This model is widely cited and clinically resonant, but n=21, single-center, and pre-dates the 2017 criteria — it should be curated as a hypothesis with EMERGING status, not as an established progression.

2.2 What the current dismech entry says

kb/disorders/Hypermobile_Ehlers-Danlos_Syndrome.yaml currently models progression as "lifelong variable multisystem disorder" plus "recurrent instability and chronic symptom burden," citing GeneReviews (PMID:20301456) on variable expression. That is defensible and conservative — the literature does not support a fixed degenerative sequence — but it omits the phase model and the trigger-event observation below.

2.3 Trigger events (the best-supported directional claim)

POTS onset in EDS/HSD "may be linked to an event such as infection, trauma, surgery, or stress" (PMID:34766441). This is the clearest available statement of temporal ordering: hEDS as a susceptibility state, with a discrete environmental precipitant converting it into overt autonomic disease. It is a review assertion, not a cohort-derived hazard ratio.

2.4 Diagnostic delay as a trajectory feature

Recognition delay is repeatedly described: "for many, there is delay in clinicians recognizing the nature of the symptoms, and recognizing EDS or HSD, leading to delays in treatment" (PMID:34766441). This means EHR-derived trajectories for hEDS are systematically distorted — the coded hEDS diagnosis typically post-dates the coded comorbidity diagnoses. Any Disease-Trajectories/ICEES-style directional signal involving hEDS should carry an explicit ascertainment-bias caveat; naive A-before-B inference will report comorbidities as causes of hEDS.

2.5 What is missing

No large longitudinal cohort establishes directionality between hEDS and any comorbidity. There is no published hEDS mortality or disability-progression study in this retrieved set. Trajectory modeling in dismech should therefore be hypothesis-typed throughout.

3. Pathomechanisms

3.1 The central fact: no validated causal gene

hEDS is the only EDS subtype without a defined molecular cause; variability in symptom spectrum, severity, and progression is attributed to age, sex, lifestyle, and expression domains of connective-tissue genes across development and postnatal life (PMID:32629534). Diagnosis remains clinical, by the 2017 criteria.

3.2 Matrix / cellular mechanisms (already partly in dismech)

The existing entry captures the strongest cell-level findings: ECM disorganization, preferential αvβ3 integrin recruitment signaling through ILK to Snail1, high MMP9, and a myofibroblast-like fibroblast transition (PMID:31409039, PMID:29587413). These are patient-fibroblast findings — candidate mechanisms, not biomarkers.

3.3 The fascia-centered framework (new synthesis)

A 2025 narrative review proposes reframing hEDS/HSD as disorders of pathological fascial remodeling, synthesizing transcriptomic, histological, and imaging findings: abnormal fascial thickness, impaired interfascial gliding, myofibroblast activation, tendon elongation, and altered tissue stiffness (PMID:40565051). Its appeal is that it offers one substrate for symptoms otherwise treated as separate comorbidities — pain, proprioceptive failure, autonomic involvement. It is a hypothesis-generating review, not primary evidence, and shares authorship with the clinical-review community it summarizes.

3.4 Mechanobiology of the comorbidities

Reduced tissue elastic modulus and ultimate strength are documented across EDS tissues; the proposal is that the comorbidities themselves may be consequences of reduced tissue stiffness, with mast cell degranulation (hEDS/cEDS) and impaired wound healing as the worked examples (PMID:35547807). This is the most explicit attempt in the literature to derive comorbidity from the primary matrix defect rather than positing independent diseases.

3.5 Neuro-immune / genetic mechanisms (2025, preprint)

The first hEDS GWAS meta-analysis (1,815 cases, 5,008 ancestry-matched controls, 6.2 M variants) reports (PMID:41001447): - Two genome-wide significant loci, including a regulatory region near ACKR3 (atypical chemokine receptor 3) on chromosome 2. Risk alleles colocalize with eQTLs in tibial nerve, alter enhancer activity, and generate an AHR transcription-factor regulatory site — implicating neuroimmune and pain signaling. - Gene-based/TWAS hits including a zinc transporter previously implicated in a rare form of EDS and a gene involved in CNS development. - LD-score genetic correlations between hEDS and joint hypermobility, ME/CFS, fibromyalgia, depression, anxiety, ASD, migraine, and GI diseases.

This last point is the single most important result for comorbidity curation: it is the first evidence that the hEDS comorbidity cluster has shared common-variant genetic architecture, rather than being purely a referral or symptom-overlap artifact — i.e. direct counter-evidence to the skeptical position in §1.4.

Status caveat: this is a medRxiv preprint (DOI 10.1101/2025.09.19.25336146). Under dismech evidence policy it should be cited only with explicit preprint flagging, and comorbidity entries should not rest on it alone.

3.6 Convergent mechanistic model

Synthesizing the above, the defensible current model is a three-layer convergence:

Unresolved connective-tissue / fascial matrix defect
  (ECM disorganization, αvβ3-ILK-Snail1, MMP9, myofibroblast transition,
   reduced tissue stiffness, impaired interfascial gliding)
        |
        +--> joint instability, recurrent injury, proprioceptive failure
        |         |
        |         +--> nociceptive input --> central sensitization
        |                (increased temporal summation, reduced EIH)
        |
        +--> vascular/connective distensibility + small fiber neuropathy
        |         |
        |         +--> orthostatic cerebral hypoperfusion, POTS
        |                (precipitated by infection/trauma/surgery/stress)
        |
        +--> visceral laxity + autonomic dysregulation + pelvic floor dysfunction
        |         |
        |         +--> disorders of gut-brain interaction, dysmotility
        |
        +--> [hypothesized] altered matrix mechanics --> mast cell degranulation
                  |
                  +--> MCAS-like multisystem symptoms

Shared genetic layer (preprint): neuroimmune/pain-signaling common variants
  correlating hEDS with ME/CFS, fibromyalgia, migraine, anxiety, depression, ASD, GI

Every arrow above is INDIRECT_UNKNOWN_INTERMEDIATES or weaker. None is a demonstrated causal pathway.

4. Implications for the dismech knowledge base

Partly superseded as of 2026-10-28. The gap list and candidate table below describe the knowledge base as it stood on 2026-07-28. Much of what they propose has since been curated — see §4.4 for what has landed and what remains open. The literature synthesis in §§1–3 is unaffected; read §4 against §4.4 rather than as a current worklist.

4.1 Gaps in the current hEDS entry

kb/disorders/Hypermobile_Ehlers-Danlos_Syndrome.yaml (655 lines) is well-evidenced but predates or omits:

Gap Supporting source
Small fiber neuropathy as a distinct phenotype (64–82%) PMID:40843452
Orthostatic cerebral hypoperfusion (79%) — more prevalent than POTS PMID:40843452
Central sensitization as a pathophysiology node (increased temporal summation) PMID:35442549
Pelvic floor dysfunction / rectal hyposensitivity PMID:40387691
Quantitative GI symptom frequencies (constipation 73%, abdominal pain 69%) PMID:35750466
Three-phase natural history as a mechanistic_hypotheses entry PMID:20140961
Fascial-remodeling mechanism branch PMID:40565051
Common-variant genetic architecture (preprint-flagged) PMID:41001447
Note that Beighton score does not index multimorbidity PMID:38779137

4.2 Candidate kb/comorbidities/ entries

Partner disorders already present in kb/disorders/, so these are curatable now:

Pair Directionality Strongest evidence Confidence
hEDS ↔ Postural Orthostatic Tachycardia Syndrome UNKNOWN (hEDS is the susceptibility state; POTS onset event-triggered) POTS 33% on tilt in n=270 (PMID:40843452); PMID:34766441 High
hEDS ↔ Irritable Bowel Syndrome / DGBI UNKNOWN Symptom prevalence table, PMID:35750466; PMID:40387691 High
hEDS ↔ Fibromyalgia UNKNOWN Central sensitization QST, PMID:35442549; genetic correlation, PMID:41001447 (preprint) Moderate
hEDS ↔ ME/CFS UNKNOWN, with explicit diagnostic-overlap caveat PMID:28186393; PMID:41001447 (preprint) Moderate
hEDS ↔ Autism Spectrum Disorder UNKNOWN Prevalence meta-analysis, PMID:40145613 Moderate
hEDS ↔ Generalized Anxiety Disorder UNKNOWN PMID:28186381 ("neuroconnective phenotype") Moderate
hEDS ↔ Migraine UNKNOWN PMID:37847487 (review-level) Low–moderate
hEDS ↔ Celiac Disease UNKNOWN PMID:40387691 (earlier-testing recommendation) Low

MCAS is not curatable as a comorbidity entry yet — there is no MCAS disorder file in kb/disorders/ (only Systemic_Mastocytosis and Maculopapular_Cutaneous_Mastocytosis, which are distinct clonal entities), and the association is actively contested (PMID:31267471 vs PMID:33980338). If curated, it must carry both sides.

4.3 Curation guardrails specific to hEDS

  1. Directionality should default to UNKNOWN. Diagnostic delay (§2.4) means EHR temporal ordering is systematically misleading for this disease.
  2. Every comorbidity entry needs a discussions block with kind: KNOWLEDGE_GAP recording that mechanism evidence is "limited and evolving" (PMID:40387691).
  3. Ascertainment bias is the dominant confound. The two largest datasets (PMID:38779137 registry, PMID:40843452 autonomic referral centre) both over-sample severely affected patients.
  4. Do not use Beighton score or hypermobility severity as a proxy for comorbidity burden (PMID:38779137).
  5. The skeptical position must be represented, not filtered out — PMID:31267471 is a peer-reviewed systematic review in a mainstream journal, and a REFUTE-typed evidence item is the honest encoding. Where one source both supports a weaker form of the claim and contradicts a stronger one, split it into two evidence items — a SUPPORT and a REFUTE, each quoting the sentence that carries it — rather than reaching for a single hedged grade. supports admits only SUPPORT, REFUTE and NO_EVIDENCE; the PARTIAL value this report originally recommended here was retired by issue #7439, and an inferential step is now carried by directness: INDIRECT instead.

4.4 What has been curated since (state on 2026-10-28)

The hEDS entry has roughly tripled, from 655 to 1,722 lines, and now cites four of this report's key references: PMID:40843452, PMID:40387691, PMID:40565051 and PMID:41001447.

Of the nine §4.1 gaps, four are closed — small fiber neuropathy, orthostatic cerebral hypoperfusion, the fascial-remodeling mechanism branch, and the common-variant/ACKR3 genetics. Four remain open: central sensitization as a pathophysiology node, pelvic floor dysfunction / rectal hyposensitivity, the three-phase natural history as a mechanistic_hypotheses entry, and the note that Beighton score does not index multimorbidity. PMID:35442549, PMID:35750466, PMID:20140961 and PMID:38779137 are still uncited by the entry, and are the sources those four gaps need.

Thirteen hEDS comorbidity entries now exist, so §4.2's table is no longer a worklist. Five of its eight candidates are curated — POTS, irritable bowel syndrome, fibromyalgia, generalized anxiety disorder and migraine. Three are still open: ME/CFS, autism spectrum disorder and celiac disease. Eight further pairs this report did not anticipate have been curated as well: asthma, complex regional pain syndrome type 1, endometriosis, gastroesophageal reflux disease, major depressive disorder, mitral valve prolapse, panic disorder, and mast cell activation syndrome.

§4.2's judgement on MCAS no longer holds, and §1.4's sourcing has been superseded. Mast_Cell_Activation_Syndrome.yaml and Monoclonal_Mast_Cell_Activation_Syndrome.yaml are both in kb/disorders/, so the blocker that report named — no MCAS disorder file to point at — is gone. The pair is curated as curation_status: CANDIDATE with directionality: UNKNOWN, which is what guardrail 1 asks for.

It also handles the contested evidence better than §4.3 item 5 anticipated, and on a newer source than either paper §1.4 discusses. Rather than PMID:31267471 (2020), it rests on PMID:40185471 — a 2025 four-database systematic review that found no study diagnosing both conditions under prespecified criteria — and splits that single paper into two evidence items: a REFUTE quoting its overall conclusion, and a SUPPORT with directness: INDIRECT quoting its own qualification that one study came close to meeting full MCAS criteria. That is exactly the split guardrail 5 prescribes, and it is a stronger encoding than the hedged single grade this report originally proposed.

Neither PMID:33980338 nor PMID:31267471 is cited there, and on this evidence neither needs to be: the 2025 review covers the same question with a stricter protocol. §1.4's account of the dispute stands as of July, but cite PMID:40185471 ahead of it.

Reference list

All references below were retrieved from PubMed and their abstracts read directly.

PMID Citation DOI
20140961 Castori M, et al. Natural history and manifestations of the hypermobility type Ehlers-Danlos syndrome: a pilot study on 21 patients. Am J Med Genet A 2010;152A:556-64. 10.1002/ajmg.a.33231
28186381 Bulbena A, et al. Psychiatric and psychological aspects in the Ehlers-Danlos syndromes. Am J Med Genet C 2017;175:237-45. 10.1002/ajmg.c.31544
28186390 Chopra P, et al. Pain management in the Ehlers-Danlos syndromes. Am J Med Genet C 2017;175:212-19. 10.1002/ajmg.c.31554
28186393 Hakim A, et al. Chronic fatigue in Ehlers-Danlos syndrome-Hypermobile type. Am J Med Genet C 2017;175:175-80. 10.1002/ajmg.c.31542
31267471 Kucharik AH, Chang C. The Relationship Between hEDS, POTS, and MCAS. Clin Rev Allergy Immunol 2020;58:273-97. 10.1007/s12016-019-08755-8
32629534 Gensemer C, et al. Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes. Dev Dyn 2021;250:318-44. 10.1002/dvdy.220
33980338 Wang E, et al. The relationship between MCAS, POTS, and Ehlers-Danlos syndrome. Allergy Asthma Proc 2021;42:243-46. 10.2500/aap.2021.42.210022
34766441 Mathias CJ, et al. Dysautonomia in the Ehlers-Danlos syndromes and hypermobility spectrum disorders. Am J Med Genet C 2021;187:510-19. 10.1002/ajmg.c.31951
34811894 Bascom R, et al. Respiratory manifestations in the Ehlers-Danlos syndromes. Am J Med Genet C 2021;187:533-48. 10.1002/ajmg.c.31953
35442549 De Wandele I, et al. Exploring pain mechanisms in hypermobile Ehlers-Danlos syndrome: A case-control study. Eur J Pain 2022;26:1355-67. 10.1002/ejp.1956
35547807 Royer SP, Han SJ. Mechanobiology in the Comorbidities of Ehlers Danlos Syndrome. Front Cell Dev Biol 2022;10:874840. 10.3389/fcell.2022.874840
35750466 Thwaites PA, et al. Hypermobile Ehlers-Danlos syndrome and disorders of the gastrointestinal tract. J Gastroenterol Hepatol 2022;37:1693-1709. 10.1111/jgh.15927
35756986 Buryk-Iggers S, et al. Exercise and Rehabilitation in People With Ehlers-Danlos Syndrome: A Systematic Review. Arch Rehabil Res Clin Transl 2022;4:100189. 10.1016/j.arrct.2022.100189
37316864 Schubert-Hjalmarsson E, et al. Central sensitization in adolescents with HSD or hEDS—a feasibility study. Pilot Feasibility Stud 2023;9:97. 10.1186/s40814-023-01320-3
37847487 Blitshteyn S. Dysautonomia, Hypermobility Spectrum Disorders and Mast Cell Activation Syndrome as Migraine Comorbidities. Curr Neurol Neurosci Rep 2023;23:769-76. 10.1007/s11910-023-01307-w
38779137 Petrucci T, et al. Phenotypic Clusters and Multimorbidity in Hypermobile Ehlers-Danlos Syndrome. Mayo Clin Proc Innov Qual Outcomes 2024;8:253-62. 10.1016/j.mayocpiqo.2024.04.001
40145613 Baeza-Velasco C, et al. Autism in the context of joint hypermobility, HSD, and EDS: A systematic review and prevalence meta-analyses. Autism 2025;29:1939-58. 10.1177/13623613251328059
40185471 Farley M, et al. Prevalence of mast cell activation disorders and hereditary alpha tryptasemia among patients with postural orthostatic tachycardia syndrome and Ehlers-Danlos syndrome: A systematic review. Ann Allergy Asthma Immunol 2025;135:97-102. (added 2026-10-28, §4.4) 10.1016/j.anai.2025.03.022
40387691 Aziz Q, et al. AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in hEDS: Expert Review. Clin Gastroenterol Hepatol 2025;23:1291-1302. 10.1016/j.cgh.2025.02.015
40565051 Wang TJ, et al. Fascial Pathophysiology in HSD and hEDS: A Review of Emerging Evidence. Int J Mol Sci 2025;26:5587. 10.3390/ijms26125587
40843452 Novak P, et al. Hypermobile Ehlers-Danlos Syndrome: Cerebrovascular, Autonomic and Neuropathic Features. Am J Med Open 2025;14:100111. 10.1016/j.ajmo.2025.100111
41001447 Petrucci-Nelson T, et al. Complex Genetics and Regulatory Drivers of hEDS: Insights from GWAS Meta-analysis. medRxiv 2025. PREPRINT 10.1101/2025.09.19.25336146

Already cited in the dismech hEDS entry and reused here: PMID:20301456 (GeneReviews), PMID:31409039, PMID:29587413.

Method: PubMed searches across hEDS comorbidity, dysautonomia/POTS, mast cell activation, psychiatric/neurodevelopmental, GI, pain mechanism, natural history, and pathogenesis axes. Abstracts were read directly for every cited PMID; no claim above is sourced from a secondary summary. No evidence snippets have been committed to KB YAML from this review — quoted figures must be re-verified against references_cache/ via just fetch-reference before use in an evidence item.